- Home
- CBZ vs ADPT Comparison
CBZ vs ADPT Comparison
Compare CBZ & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBZ
- ADPT
- Stock Information
- Founded
- CBZ 1987
- ADPT 2009
- Country
- CBZ United States
- ADPT United States
- Employees
- CBZ N/A
- ADPT N/A
- Industry
- CBZ Business Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBZ Consumer Discretionary
- ADPT Health Care
- Exchange
- CBZ Nasdaq
- ADPT Nasdaq
- Market Cap
- CBZ 3.0B
- ADPT 2.6B
- IPO Year
- CBZ N/A
- ADPT 2019
- Fundamental
- Price
- CBZ $52.54
- ADPT $14.80
- Analyst Decision
- CBZ
- ADPT Strong Buy
- Analyst Count
- CBZ 0
- ADPT 10
- Target Price
- CBZ N/A
- ADPT $15.70
- AVG Volume (30 Days)
- CBZ 605.5K
- ADPT 1.6M
- Earning Date
- CBZ 10-29-2025
- ADPT 11-05-2025
- Dividend Yield
- CBZ N/A
- ADPT N/A
- EPS Growth
- CBZ N/A
- ADPT N/A
- EPS
- CBZ 1.66
- ADPT N/A
- Revenue
- CBZ $2,675,607,000.00
- ADPT $252,754,000.00
- Revenue This Year
- CBZ $55.67
- ADPT $36.43
- Revenue Next Year
- CBZ $6.13
- ADPT $12.31
- P/E Ratio
- CBZ $32.32
- ADPT N/A
- Revenue Growth
- CBZ 59.19
- ADPT 42.57
- 52 Week Low
- CBZ $50.51
- ADPT $4.27
- 52 Week High
- CBZ $90.13
- ADPT $17.89
- Technical
- Relative Strength Index (RSI)
- CBZ 45.20
- ADPT 41.15
- Support Level
- CBZ $53.78
- ADPT $16.51
- Resistance Level
- CBZ $55.85
- ADPT $17.75
- Average True Range (ATR)
- CBZ 1.79
- ADPT 0.84
- MACD
- CBZ 0.27
- ADPT -0.32
- Stochastic Oscillator
- CBZ 39.36
- ADPT 1.43
About CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).